

2 March 2026

DR SAMA BALASUBRAMANIAN APPOINTED TO SCIENTIFIC ADVISORY BOARD

- EVE appoints Dr Sama Balasubramanian to its Scientific Advisory Board.
- Dr Balasubramanian is a Fellow of the Royal Australasian College of General Practitioners and a Fellow of the Australasian Chapter of Sexual Health Medicine (RACP).
- Brings extensive clinical, research and governance experience in sexual medicine and men's health.
- Strengthens EVE's Scientific Advisory Board as Libbo™ enters commercial rollout and the Company advances its sexual and reproductive health pipeline.

EVE Health Group Limited (ASX: EVE, EVE or the Company) is pleased to announce the appointment of Dr Sama Balasubramanian as a member of its Scientific Advisory Board (SAB).

Dr Balasubramanian is a Specialist Sexual Health Physician and General Practitioner with extensive experience across clinical practice, medical education and health governance. He is a Specialist Physician in Sexual Medicine with Sydney Men's Health and holds fellowships with both the Royal Australian College of General Practitioners and the Australasian Chapter of Sexual Health Medicine (RACP). He is also a Fellow of the European Committee of Sexual Medicine and has an Advanced Masters in Psychosexual Therapy with the University of Sydney.

In addition to his clinical roles, Dr Balasubramanian has held a number of senior leadership positions, including Chair of the Training Committee in Sexual Health Medicine with the Royal Australasian College of Physicians and President of General Practice Registrars Australia. His work spans curriculum development, clinical governance, trainee supervision and national policy advisory roles.

Dr Balasubramanian's appointment reflects his recognised expertise in men's health and sexual medicine, including experience in the evaluation and development of therapeutics for erectile dysfunction and related conditions. He joins EVE's SAB at a time when the Company has commenced the commercial launch of Libbo™, its oral dissolving film treatment for erectile dysfunction, and is building an integrated digital prescribing and fulfilment platform to support scalable national access.

The SAB provides independent strategic, scientific and clinical guidance to the Board and executive management. Its role includes advising on product development strategy, clinical trial design,

evidence generation, therapeutic positioning and standards of care across EVE's focus areas of sexual and reproductive health.

EVE Executive Director and Chief Scientific Officer, Dr Stuart Gunzburg, said: "We are pleased to welcome Dr Sama Balasubramanian to EVE's Scientific Advisory Board. Sama brings a rare combination of deep clinical expertise in sexual health medicine, leadership in medical education and strong governance experience.

As we advance the commercial rollout of Libbo and continue to expand our sexual and reproductive health pipeline, his insights into standards of care, prescriber engagement and clinical evidence generation will be highly valuable to the Company."

Dr Sama Balasubramanian said: "I am pleased to join EVE's Scientific Advisory Board at an important stage in the Company's development. The SAB has a key role in providing independent scientific and clinical guidance to support evidence-based product development.

I look forward to contributing my experience in sexual health medicine and men's health to help inform EVE's ongoing research, clinical and commercial strategy."

Authorised for release by the Board of Directors.

Company enquiries

+61 8 6465 5500

info@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. The company's lead assets include Dyspro, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo, an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. Both products leverage EVE's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes, representing near-term commercial opportunities in large, underserved global markets.

EVE is building a vertically integrated health platform that combines proprietary pharmaceutical products with digital education, patient engagement and prescribing pathways. Through its dedicated information platforms, ReclaimMyCycle.com (women's health) and StiffIssue.com (men's health), the Company provides condition-focused education, reduces stigma and supports earlier engagement with appropriate care. These platforms integrate with telehealth and pharmacy fulfilment networks to enable responsible, scalable access to treatment within a regulated healthcare framework.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.